Sign in to view content

Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of Great Than or Equal to 4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S

Allen Chiang, MD, FASRS

Video
Published 2019

Allen Chiang, MD

Diabetic Retinopathy Part II Symposium

Related

Sustained Diabetic Retinopathy Severity Improvement With Intravitreal Aflibercept in DME: Post Hoc Analysis of VISTA and VIVID
Rishi P. Singh, MD
Annual Meeting Talks
2019
BiWeekly Anti-VEGF Dosing for Chronic Refractory Neovascular Age-Related Macular Degeneration Unresponsive to Standard Monthly Dosing
Eric W Schneider, MD
Annual Meeting Talks
2019
Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022

Category: Diabetic Retinopathy

See more